US Food and Drug Administration Principal Deputy Commissioner Namandjé Bumpus’ decision to leave by the end of the year means there is no obvious, internal candidate to serve as acting commissioner in January.
US FDA Principal Deputy Commissioner Bumpus Leaving At Year’s End, Creating Leadership Void
Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.
